Investor Relations

Company Overview

BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Designed to address alcoholism and certain opioid addictions, the BioCorRx® Recovery Program is used by independent treatment centers or physicians in the United States. The program consists of BioCorRx’s proprietary cognitive behavioral therapy (CBT) program and peer recovery support mobile application and may include the use of certain medications typically used for the treatment of substance use disorder (SUD). Which medication used, if any, is at the sole discretion of the treating physician in consultation with their patient. The most common medication used in the program is naltrexone in various forms (oral, injectable, implantable pellet). The company does not sell, manufacture, or compound any drugs or pharmaceuticals. The company also has a pharmaceutical subsidiary, BioCorRx Pharmaceuticals, which is developing medications for future regulatory approval. It’s lead candidate is BICX102, a biodegradable implantable naltrexone pellet for alcohol and opioid use disorders.

Latest Financial Results

Q2 2020

Quarter Ended Jun 30, 2020

Stock Information

Symbol

OTCQB: BICX

Price

Change

Volume

52 week Low/High

Day Low/High

Contact Information

Investor Relations
Crescendo Communications, LLC
T: 212-671-1020 x304
bicx@crescendo-ir.com

investors@biocorrx.com

Transfer Agent
VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
www.vstocktransfer.com